Additional Chalcogen Bonded Directly To The Carbon Patents (Class 544/40)
  • Publication number: 20140113890
    Abstract: The invention provides 4-amino-4-oxobutanoyl peptides of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R1, R6-R8, R16, R18, R19, M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. The 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a 4-amino-4-oxobutanoyl peptides as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptides and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
    Type: Application
    Filed: December 23, 2013
    Publication date: April 24, 2014
    Applicant: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Avinash Phadke, Dawei Chen, Venkat Gadhachanda, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Atul Agarwal, Ha Young Kim, Shuoming Li, Cuixian Liu, Suoming Zhang, Milind Deshpande
  • Publication number: 20130230771
    Abstract: A rechargeable metal ion cell comprising: an anode comprising at least one metal; a charge-carrying electrolyte comprising a charge carrying medium and at least one metal salt; and an organic polymer cathode, wherein such cathode comprises at least one N-substituted polyphenothiazine polymer [polymer (P)], such polymer (P) comprising at least one N-substituted phenothiazine recurring unit of formula: wherein R? is an electron-withdrawing group comprising at least one heteroatom selected from the group consisting of O, S, P, and N.
    Type: Application
    Filed: November 16, 2011
    Publication date: September 5, 2013
    Applicants: UNIVERSITE JOSEPH FOURIER, SOLVAY SA
    Inventors: Alain Deronzier, Thibault Godet-Bar, Jean-Claude Lepretre, Jean-Yves Sanchez
  • Patent number: 6638713
    Abstract: The invention provides methods of using a compound as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and kits for performing these methods.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: October 28, 2003
    Assignee: Aurora Biosciences Corporation
    Inventors: Lewis R. Makings, Gregor Zlokarnik
  • Patent number: 6583138
    Abstract: The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: June 24, 2003
    Assignee: Eisai Co., Ltd.
    Inventors: Mitsuaki Miyamoto, Tatsuya Yoshiuchi, Keizo Sato, Motohiro Soejima, Takashi Sato, Koichi Kikuchi, Hiroyuki Yoshimura, Katsuhiro Moriya, Yoshinori Sakuma, Shigeru Akasofu, Koji Yamada
  • Patent number: 6420130
    Abstract: The invention provides a compound, useful as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and candidate drugs identified by these methods.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: July 16, 2002
    Assignee: Aurora Biosciences Corporation
    Inventors: Lewis R. Makings, Gregor Zlokarnik
  • Patent number: 5362871
    Abstract: A process for the direct and regioselective functionalization of phenothiazine which allows one to introduce an SH group in position 2, said process comprising the sulfination or sulfonation of the phenothiazine N-protected with an alkoxycarbonyl, an alkylsulfonyl or an arylsulfonyl group, the reduction of the produce obtained to give the N-protected 2-mercapto-phenothiazine, and the deprotection of the nitrogen atom. The thus-obtained 2-mercapto-phenothiazine is an important intermediate for the preparation of pharmacological active compounds.
    Type: Grant
    Filed: February 12, 1992
    Date of Patent: November 8, 1994
    Assignee: Zambon Group S.p.A.
    Inventors: Claudio Giordano, Maurizio Paiocchi, Paolo Cavalleri
  • Patent number: 5142045
    Abstract: Novel polymers containing 6,6,6-tricyclic moieties pendant from the polymer backbone, their novel monomers, and novel conductive polymers formed by doping the novel polymers with an electron acceptor compound. The novel polymers are easily synthesized, are soluble in various solvents, and are more stable than conductive polymers having the tricyclics as repeating units in the polymer backbone. A preferred tricyclic is phenothiazine.
    Type: Grant
    Filed: May 27, 1988
    Date of Patent: August 25, 1992
    Assignees: Aisin Seiki Kabushiki Kaisha, The Regents of the University of Michigan
    Inventors: Robert Zand, Shinji Nezu, Selim Kusefoglu
  • Patent number: 4874857
    Abstract: Dyestuffs of the formula ##STR1## in which R.sub.1, R.sub.2 =H, Cl, Br, optionally substituted C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, carbonyl, aryloxy optionally substituted carboxamide or acylamino,R.sub.3 =H, optionally substituted C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, Cl or Br,R.sub.4 =H or alkyl,B=an aliphatic or arylene bridge member,Z=H or fiber-reactive radical,n=0 or 1.These dyestuffs are highly suitable for dyeing and printing hydroxyl- and amides-containing materials and produce red dyeings and prints having good wet- and light-fastness properties.
    Type: Grant
    Filed: September 29, 1987
    Date of Patent: October 17, 1989
    Assignee: Bayer Aktiengesellschaft
    Inventor: Wolfgang Harms
  • Patent number: 4117127
    Abstract: N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.
    Type: Grant
    Filed: October 21, 1977
    Date of Patent: September 26, 1978
    Assignees: Mitsubishi Chemical Industries Ltd., Shosuke Okamoto
    Inventors: Shosuke Okamoto, Akiko Hijikata, Ryoji Kikumoto, Yoshikuni Tamao, Kazuo Ohkubo, Tohru Tezuka, Shinji Tonomura